43 FY 2013 Drug GMP Warning Letters Hit Data Integrity, Training and More
This article was originally published in The Gold Sheet
Executive Summary
FDA’s 43 fiscal year 2013 drug GMP warning letters highlighted problems related to data integrity, inadequate testing of raw materials and inadequate employee training. These trends were associated with increases in warning letters to manufacturers in India and to U.S.-based compounding pharmacies.